News about "weight management"

Biocon Launches its Glucagon-like Peptide-1 (GLP -1), Liraglutide in Netherlands

Biocon Launches its Glucagon-like Peptide-1 (GLP -1), Liraglutide in Netherlands

Biocon has launched its GLP-1 drug–device combination, Liraglutide, in the Netherlands, where it will be marketed under the brand names Diavorin for diabetes and Vobexoryn for chronic weight management.

Weight Management | 15/12/2025 | By News Bureau 108

Eli Lilly Reports Positive Phase 3 Topline Results for Oral GLP-1 Orforglipron in Type 2 Diabetes

Eli Lilly Reports Positive Phase 3 Topline Results for Oral GLP-1 Orforglipron in Type 2 Diabetes

Eli Lilly and Company has announced positive topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials evaluating orforglipron for the treatment of type 2 diabetes.

Weight Management | 16/10/2025 | By Dineshwori 241

Wegovy Cuts Food Noise, Cagrilintide Delivers Significant Weight Loss: Novo Nordisk Unveils New Data at EASD 2025

Wegovy Cuts Food Noise, Cagrilintide Delivers Significant Weight Loss: Novo Nordisk Unveils New Data at EASD 2025

Novo Nordisk presented new findings from its Wegovy and Cagrilintide trials in obesity management at the ongoing European Association for the Study of Diabetes (EASD) 2025 congress in Vienna, Austria.

Weight Management | 17/09/2025 | By Dineshwori 312

Cipla to Enter Weight Management Segment, Expands Focus on Oncology and CNS Therapies

Cipla to Enter Weight Management Segment, Expands Focus on Oncology and CNS Therapies

Cipla is set to enter India’s growing weight management market as part of its broader strategy to expand across emerging therapeutic segments.

Weight Management | 14/07/2025 | By Dineshwori 206

Zealand Pharma and Roche to Develop and Commercialize Petrelintide

Zealand Pharma and Roche to Develop and Commercialize Petrelintide

The two companies will co-develop and co-commercialize petrelintide and combination products with petrelintide, including a fixed-dose combination product of petrelintide and CT-388, Roche’s lead incretin asset and potential best-in-class GLP-1/GIP receptor dual agonist.

Weight Management | 15/03/2025 | By Aishwarya 318


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members